Chikungunya Virus
5
Pipeline Programs
2
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 4 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Bavarian NordicDenmark - Kvistgard
4 programs1
3
CHIKV VLP vaccinePhase 3Vaccine1 trial
CHIKV VLP/adjuvantPhase 31 trial
CHIKV VLP/adjuvantPhase 31 trial
CHIKV VLP, adjuvantedPhase 21 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Bavarian NordicCHIKV VLP vaccine
Bavarian NordicCHIKV VLP/adjuvant
Bavarian NordicCHIKV VLP/adjuvant
Bavarian NordicCHIKV VLP, adjuvanted
ModernaVAL-181388
Clinical Trials (5)
Total enrollment: 4,476 patients across 5 trials
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
Start: Jun 2025Est. completion: Dec 2028720 patients
Phase 3Recruiting
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
Start: May 2022Est. completion: Aug 2023413 patients
Phase 3Completed
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
Start: Sep 2021Est. completion: Apr 20233,258 patients
Phase 3Completed
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
Start: Oct 2021Est. completion: May 202225 patients
Phase 2Completed
Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
Start: Jul 2017Est. completion: Mar 201960 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 4,476 patients
2 companies competing in this space